- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- ALEMBIC PHARMA
ALEMBIC PHARMA Share Price 
(APLL)
Here is the latest stock price and chart of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Nov 13, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)589.25 | Open (Rs) 592.75 | High (Rs) 592.75 | Low (Rs) 588.00 |
| % Change-0.15 | Volume 853 | Value (Rs) 502,818 | 52-Week H/L 664.00 / 412.40 |
| Live NSE Quotes | Nov 13, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)590.55 | Open (Rs) 591.95 | High (Rs) 592.70 | Low (Rs) 589.85 |
| % Change-0.30 | Volume 19,366 | Value (Rs) 11,431,841 | 52-Week H/L 664.00 / 414.40 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 27.77 | P/E Ratio (x) 21.22 | Market Cap (Rs m) 111,085.41 | P/BV (x) 5.00 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
ALEMBIC PHARMA Share Price Today:
ALEMBIC PHARMA last traded price was down 0.2% to Rs 589.3 on the BSE. On the NSE, ALEMBIC PHARMA last traded price was down 0.3% to Rs 590.6. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.8%. And the benchmark S&P BSE SENSEX was at 35,144.5 (up 1.0%).
Over the last 30 days, the ALEMBIC PHARMA share price is down 1.1%. And over the last one year, ALEMBIC PHARMA share price is up 14.7%.
|
| |
Today's Market
Of Retail Inflation, Growth in India's Aviation Sector, and Top Cues in Focus Today(Pre-Open)
Share markets in India witnessed buying interest during closing hours yesterday and ended the day on a positive note.
Related Views On News
ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)
Oct 23, 2018 | Updated on Oct 23, 2018For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)
Jul 30, 2018 | Updated on Jul 30, 2018For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)
Nov 9, 2018All blue chip companies are large caps but all large caps are not blue chips.
Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)
Nov 6, 2018If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.
Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)
Nov 2, 2018We believe insider buying is one of the strongest smart money indicators.
Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)
Nov 1, 2018PersonalFN explains the importance of being prepared for your child's future.
Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)
Nov 2, 2018PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.
MoreTRACK ALEMBIC PHARMA
- Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ALEMBIC PHARMA
ALEMBIC PHARMA - ADCOCK INGRAM COMPARISON
COMPARE ALEMBIC PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.